Osteoporotic vertebral compression fracture
Conditions
Interventions
AI-assisted Follow-up Group:AI-assisted follow-up with red-flag escalation mechanism
Conventional (Human-led) Follow-up Group:Conventional follow-up/education with red-flag escalation mechanism
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age >= 60 years; 2. Imaging confirms OVCF, has undergone PVP/PKP/posterior fixation, and postoperative period <= 7 days; 3. Planned to receive alendronate (oral) or denosumab (subcutaneous injection); 4. Patient or primary caregiver has the ability to participate in WeChat follow-up; 5. Signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. History of or concurrent malignant tumors, or severe liver/kidney dysfunction; 2. Severe cognitive/mental disorders (e.g., MMSE <=18) preventing cooperation; 3. Expected lifespan <12 months or extremely unstable condition; 4. Contraindication or allergy to alendronate/denosumab; 5. No reliable contact information or expected inability to complete 12-month follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-month adherence for oral alendronate (PDC >=80%);On-time denosumab dosing (both doses within 6-month ±4-week windows); | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain intensity (VAS, 0–100 mm);Oswestry Disability Index (ODI, %);Fracture-Related Index (FRI, %);Mean duration of follow-up encounter;Cumulative fall incidence;Follow-up response rateFollow-up response rate;Patient satisfaction (5-point Likert scale);Escalation rate of red-flag events to human intervention;Cumulative all-cause readmission rate;Rate of clinician edits to AI responses;Cumulative refracture incidence; | — |
Countries
China
Contacts
Public ContactHao Jie
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed